Abstract. Resveratrol is a stilbene compound found in grapes and other sources. In this study we examined the effects of trans-resveratrol (4.38 -438 μM/ implant) in the vasculogenesis of yolk-sac membranes and its capacity to improve chick embryo growth. High concentrations of the stilbene (43.8 -438 μM) significantly inhibited early vessel formation, decreasing the percentage vitelline vessels of 3.5-day embryos by 50% compared to the control. In addition, basic fibroblast growth factor-stimulated vasculogenesis (140% of vessels as compared to control) was partially reversed by t-resveratrol (35% of inhibition) and treatments with cyclooxygenase inhibitors (acetylsalicylic acid and indomethacin) as well a protein-kinase C (PKC) activator (phorbol-12,13-dibutyrate) decreased the vessel number to 60%, 50%, and 44%, respectively. Treatments with t-resveratrol (4.38 -43.8 μM/ implant) significantly increased the body length of embryos incubated in vitro uncoupled from any impairment in the body shape or detectable embryotoxic effect. We suggest that the antivasculogenic activity and the enhancement in embryonic growth promoted by non acute treatments with t-resveratrol were, at least in part, due to PKC inhibition. We suggest that t-resveratrol can be usable not only as a reliable functional nutriment, but also is useful for the development of prophylactic and / or therapeutic agents for treatment of angiogenic-degenerative diseases.
Introduction
During embryogenesis the early vasculature is established by vasculogenesis, which is a process defined as the formation of primordial blood vessels from in situ differentiation of mesodermal progenitor endothelial cells (angioblasts) to endothelial cells (1, 2) . These precursor cells are recruited from mesoderm areas adjacent to embryo or originated by local cell division and organize blood islands. Afterwards, these cell clusters lay down a primary vascular plexus (3, 4) .
A subsequent remodeling of the vascular network gives rise to a more refined microvasculature (5) . The sprouting and proliferation of capillaries from the preexisting vessels (angiogenesis), accompanies the growth and shaping of the body, but angiogenesis can also occur through intussusception, a non sproutingdependent process that is a longitudinal division of an existing vessel (6, 7) .
The paradigm by which vessel formation via vasculogenesis only occurs during embryogenesis, and also that angiogenesis is the only process of vessel formation present in the adult organism, has been recently reconsidered. Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), the most extensively studied angiogenesis inducers (2, 8) , are also involved in the process of vasculogenesis (9) . Moreover, due to evidence that the recruitment of endothelial precursor cells (inherent to embryo vasculogenesis) may also be an event recapitulated in adult vessel formation, there is currently consensus about the presence of endothelial cell progenitors in adults, possibly promoting de novo vessel formation (adult vasculogenesis) (for reviews, see refs. 10 and 11). Such a process would impact neoangiogenesis, which is associated with tumors (8, 12) .
Since 1971, when Judah Folkman (12) introduced the concept of antiangiogenesis, a great number of angiogenesis inhibitor agents as well as angiogenesis activators have been characterized. From the point of view of potential clinical applications, the efficacy shown by natural angiostatic agents in association with more reduced side effects as compared to conventional pharmaceuticals, has motivated intensive investigations by many laboratories (13, 14) .
Previous investigations have indicated that polyphenolic compounds from wine and also green tea are capable of inhibiting several key events of angiogenesis such as expression of proangiogenic factors and proliferation and migration of endothelial cells and vascular smooth muscle cells by redox-sensitive as well as redoxinsensitive mechanisms. Moreover, some antiangiogenic properties of polyphenols have been recorded on the chick embryo chorioallantoic membrane and in mice cornea assays (for a review, see ref. 15) .
Trans-resveratrol (trans-3,5,4'-trihydroxystilbene), a polyphenolic phytoalexin synthesized by several plant species, is a stilbenoid derivative (product of the enzyme stilbene synthase) that has been referred to as a phytoestrogen due to its structural and biological properties (estrogenic action in animal cells), including agonistic activity for estrogen receptors (16) . In accordance with Stervbo and collaborators (17) t-resveratrol is currently available as a nutritional supplement but not as a therapeutic agent (despite its record as an investigational drug). Its amount varies greatly in foods, but it is mainly found in the skin of peanuts, blueberries, grapes, and in some pines.
Naturally (20) . Among a number of synthesized hydroxystilbene derivatives, the most potent appears to be piceatannol (3,3',4,5-tetrahydroxystilbene) with a IC 50 of 4.3 μM. Those compounds with neighbouring hydroxyl functions were the most effective and methylation of OH groups abolished the inhibition (18) .
A number of studies emphasized that t-resveratrol may be related to the protective activity of red wines in some kinds of cardiovascular pathologies; and in fact, stilbene was described to have antioxidant (21) as well as antimutagenic and antitumoral effects (16, 22) . Furthermore, the specificity of t-resveratrol in inhibiting COX enzymes (COX-1) was also attributed to some anti-inflammatory properties (23) . Additionally, its antimitotic and proapoptotic activities have been demonstrated in vitro as well its antiangiogenic effects (24 -26) .
In the current study, we are focused on the capacity of t-resveratrol to inhibit the early vitelline blood vessel formation (focusing on vasculogenesis) by assaying in vitro and in vivo yolk-sac membranes (YSMs) from chick embryos. Moreover, due to well know phytoestrogenic features of that stilbene, we also measured the embryo body length to determine if its effects on vessels could be correlated with changes in the pattern of embryonic growth.
Materials and Methods

Reagent and chemicals
The materials were purchased from the following commercial sources: trans-resveratrol, acetylsalicylic acid (ASA), and indomethacin (Sigma, St. Louis, MO, USA); phosphate-buffered saline (PBS) and methylcellulose (MC) (Aldrich, Milwaukee, WI, USA); BactoAgar ® and penicillin-streptomycin (Gibco, Auckland, New Zeland); bFGF (Intergen, Purchase, NY, USA); phorbol-12,13-dibutyrate (PDBu) (Calbiochem-Novabiochem, La Jolla, CA, USA); GF109203X (LC Laboratory, Boston, MA, USA); hydrocortisone (HC) (Biobras, São Paulo, SP, Brazil). Absolute ethanol and sodium chloride (NaCl) were obtained from Reagen (Rio de Janeiro, RJ, Brazil).
Animals
Pathogen-free fertilized chicken eggs (n = 8), supplied by poultry producers (Macedo Koerich, SC, Brazil), were previously kept in a humidified (33%) incubator at 37.5°C for 36 h (E3.5, embryonic day; stage 10 -HH) (27) , in accordance with the described in vitro whole embryo culture method.
Chick whole embryo in vitro assay
The ability of the substances to inhibit vasculogenesis was determined by the YSM in vitro assay. This method was adapted essentially from the chorioallantoic membrane (CAM) assay, which was carried out to evaluate angiogenesis (28 -30) .
Each substance under investigation was adsorbed on MC (0.45%) and the solution was air-dried on a Teflon ® -coated metal tray before being applied to the developing extra embryonic membranes for testing of vasculogenesis by t-resveratrol.
After a preliminary incubation period of 36 h (E1.5), the eggs were removed from the incubator and handled according to the procedures previously described by Chapman and co-workers (31) . In brief, the whole chick embryos surrounded by yolk-free segment of vitelline membrane were mounted into slides and cultured for 48 h, with the ventral side placed upward in Petri dishes containing solid agar-albumen medium (0.72 g BactoAgar; 120 ml of thin albumen and 120 ml of 7.19 g / l NaCl simple saline) in an incubator at 37°C with saturated humidity and atmosphere of 5% CO 2 in air.
The treatment was performed by implanting diskshaped MC supports (5-μl volume, 2-mm diameter; one disk per embryo) in the outer one-third surface of the 1.5-day YSM, near the embryo, where blood islands were present together with early capillaries. Blank MC disks (ultra-filtered water as solvent, pH 7.2) and disks containing 43.04 mM of the glucocorticoid HC sodium succinate (this corticosteroid compound used in the treatment of arthritis and inflammation has also been referred to as an angiogenesis inhibitor) were used as negative and positive controls, respectively [adapted from Gagliardi and Collins (32) ]. As an additional positive control, which enables a comparison with a non-steroidal anti-inflammatory drug (NSAID) activity pattern, the effects of administration of ASA (2-acetoxybenzoic acid, 1 mM/ disk) and also indomethacin (500 μM/ disk) were evaluated in the YSM in vivo assay with regard to vasculogenesis inhibition by blockade of the COX pathway.
Stock solutions of 1 mM t-resveratrol ( Fig. 1 ) in absolute ethanol and 11.25 mg / ml MC (150,000 / Mol, vis 140 cp) in water were kept (−20°C) in 500 μl aliquots and diluted to work concentrations (4.38 -438 μM/ disk, 1 -100 μg / ml) in the same vehicle previously used (alcohol was removed by evaporation during the polymerization of MC-disk supports).
Complementally, to evaluate the effects of cotreatment of the stilbene under study with an angiogenic activator, two additional experimental groups were treated with bFGF (50 ng / disk) administered alone or in association with t-resveratrol (43.8 μM/ disk).
Also, in order to examine the effects of t-resveratrol in the PKC-modulated vessel formation, we performed additional experiments with phorbol-12,13-dibutyrate (PDBu, 10 μM/ disk), a PKC activator, administered alone or in association with t-resveratrol. Next, PDBu was co-administered with GF109203X (PKC inhibitor, 5 μM/ disk).
HC (43.04 mM / disk) was diluted in sterile ultrafiltered water immediately before use. Due to high risk of embryonic mortality or occurrence of a teratogenic effect potentially exerted by steroid compounds in developing embryos earlier than E2 (36 h), the HC was administered on YSMs by means of an in vivo assay (2 day-embryos were cultured in the egg). The in vivo assay was also performed in the treatments with bFGF, PDBu, and GF109203X. After the assay, the plates containing the 3.5-day embryos (E3.5) were removed from the incubator and the vascular area surrounding the supports was analyzed by transillumination microscopy (25×). Inhibition of vasculogenesis was determined by decrease in vessel number and expressed as the percentage vessel intercepting the limit of the disk compared to the control (vehicle).
Embryonic growth assay
At the end of the total incubation, embryos of all experimental groups were desensitized at −20°C (freezer) for 30 min and quickly euthanized by hypothermia, by placing the eggs into a −20°C freezer, with an atmosphere of liquid N 2 (in accordance with the procedures of Institutional Animal Care and Use Committee / IACUC -USA). Afterwards, the embryos were dissected from the ovular membranes, fixed in 10% formaldehyde, and then examined with regard to body total length by comparison of the measures based on the sum of segments defined as head flexure -cervical flexure -curled tail axis.
All animal studies were carried out in accordance with the procedures outlined by "NIH" as well by "Guiding Principles for the Care and Use of Laboratory Animals"/ The Japanese Pharmacological Society guidelines and defined in the protocol number 256/ proc.23080.028649 / 2003-07 / CEUA/ UFSC, of the Committee for Care and Ethical Use of Animals on Research (CEUA / UFSC, Florianópolis, SC, Brazil).
Data analyses and statistics
Data are represented as means ± S.E.M. obtained from at least two independent experiments. The statistical analyses were performed using one-way analysis of variance (ANOVA) and the Tukey (HSD) method. The influences of substance, concentration, as well as site and treatment period were tested. Effects were considered to be statistically significant at P values less than 0.05 (*).
Results
The YSM assay was first used to determine whether t-resveratrol displayed early antivascular activity. We evaluated the vascularity in 3.5-day chick embryos (E3.5) cultured in vitro together with yolk-free YSMs. By two days after implantation (performed after 1.5 day of egg incubation: E1.5), the control YSMs clearly exhibited physiologically developed, primary newly formed vitelline vessels, formed independently of any exogenous stimulus ( Fig. 2A) . Whereas the control developed an average of 26 early vitelline vessels on the disk limits, those groups treated with t-resveratrol (4.38 -438 μM/ disk) exhibited 88% -54% vessels around the disk, as compared to the control (blank disks), which confirms the antivasculogenic effect of the stilbene, independent of yolk constituents factors (Figs. 2B and 3) .
It may be considered that the high doses of tresveratrol (43.8 -438 μM/ disk) were more effective in inhibiting vessel formation in the yolkless YSM of 3.5-day chick embryos in groups cultured in vitro than in vivo culture of 4-day embryos treated with HC (43.04 mM / disk, which showed 58% vessels on the disk limit). These effects are due to distinct ages (developmental times of 1.5 and 2 days, respectively) of embryos treated in the two culture models (inset of Fig. 2 ).
As demonstrated in Fig. 4 , the experimental groups treated with ASA (1 mM / disk) and indomethacin (500 μM/ disk) exhibited 60% and 51% vessels, respec- Fig. 2 . Photographs of the inhibitory effect of t-resveratrol on vascularization of 3.5-day yolk-sac membranes (YSM) surrounding chick embryos (arrows). In each egg, one control (vehicle) or one drug-containing disk-shaped support was placed on the 1.3-day-old YSM where blood islands were still present; A: Negative control (methylcellulose only); B: t-resveratrol (43.8 µM/ disk). Bars = 5 mm. Fig. 3 . Inhibitory effect of t-resveratrol on vascularization of 3.5-day yolk-sac membranes (YSMs) of chick embryos. The controls were treated with vehicle (methylcellulose) and hydrocortisone (HC, 43.04 mM /disk), which was used as a positive control (in the inset). Results are expressed as the number of microvessels around the drug-containing disk (2-mm diameter) as a percentage of microvessels in the control. Each bar represents the mean ± S.E.M. of eight eggs. *P<0.05, between treatments (arrow); **P<0.01, vs control.
tively, as compared to the control (Fig. 4A) . However, a sharp blockade of vasculogenesis was also verified, and a concomitant vessel regression (Fig. 4 : C and D) in association with growth inhibition and embryonic death (Fig. 4B) .
Different from the effects recorded in the treatments with ASA and indomethacin, the antivasculogenic action promoted by t-resveratrol did not result in apparent dimorphic features or any detectable embryotoxic effect. Furthermore, embryos that had been early exposed to the highest concentration of t-resveratrol (438 μM/ disk) during the three and half days of the experiment and then additionally incubated for at least eight days more (data not shown) still kept their viability features.
Since a 140% enhancement in vascular density around the disk limits on the YSM was attained by treatment with bFGF (Fig. 5) , we then investigated the effect of t-resveratrol (43.8 μM/ disk) under the concomitant action of bFGF, added to the respective disks. Figure 5 shows that the stilbene partially reverses the bFGF angiogenic effect.
As shown in the Fig. 5 , the treatment with PDBu (10 μM/ disk) alone significantly decreased to about 44% the percentage vessels as compared to the control, whereas its association with t-resveratrol (43.8 μM / disk) lowered that percentage roughly by half (23.5% vessels in the disk limit). The co-treatment of PDBu (10 μM/ disk) with the PKC inhibitor (GF109203X) afforded a significant decrease to 10.5% in the content of vitelline vessels.
In order to assess the antivasculogenic effect of tresveratrol on measurements of embryonic growth, we determined the total body length of 3.5-day chick embryos in treated and control groups. As demonstrated in the Fig. 6 , the stilbene (4.38 -43.8 μM/ disk) increased the body length in 40% as compared to the control group (vehicle, which presented an average length of 13.95 ± 0.40 mm).
Nevertheless, as can be seen in the Fig. 6 , the treatment with t-resveratrol (438 μM/ disk), as well as the administration of HC (43.04 mM / disk, inset in the Fig. 6 ), were ineffective in yielding any change in the body length standard curves of chick embryos as compared to the control (vehicle).
It should be also noted that the angiogenic growth factor (50 ng / disk bFGF) administered alone as well as in association with t-resveratrol (43.8 μM/ disk) were unable to enhance the increase rates of embryonic body length (Fig. 7) . Indeed, co-treatment abolished the stimulant effect promoted by stilbene on growth.
Discussion
In this study we have presented evidences that tresveratrol substantially inhibited the early vessel formation (vasculogenesis) in the yolkless vitelline membranes (YSMs) of chick embryos cultured in vitro. The inhibitory effects on the ongoing vascularization (angiogenesis) exerted by polyphenols such as quercetin and t-resveratrol had already been investigated (14, 24) .
It is generally accepted that polyphenols inhibit cell development. In fact, previous works demonstrated that t-resveratrol influences the proliferation and apoptosis of human endothelial cell as well as tumor cells in a dose-dependent way (24) . Our findings are in accordance with results obtained by Szende and collaborators (33) , who reported that while concentrations of t-resveratrol (0.1 -1.0 μg / ml, 0.438 -4.38 μM) showed a non-inhibitory effect on the endothelial cells (and even accelerated the cell proliferation), the high concentrations (10 -100 μg / ml, 43.8 -438 μM) decreased the mitotic activity and induced cell death (apoptosis). Moreover, Igura and co-workers (24) had also demonstrated that t-resveratrol inhibited cell growth (6 -10 μM) and migration (25 -100 μM) in bovine aorta endothelial cells as well endothelial tube formation (6 -100 μM).
The findings in the present study, concerning the roughly 50% inhibition caused by t-resveratrol at doses of 43.8 and 438 μM/ disk (10 -100 μg / ml) in the early vascularization of chick embryos, were very similar to the inhibition level exhibited by HC (43.04 mM / disk, positive control). t-Resveratrol (43.8 μM/ disk) reverted the well-known pro-vascular effect of exogenous bFGF (50 ng / disk), which induces pluripotent cells from the blastodisk of the chick to undergo vasculogenesis (3). As demonstrated, the stilbene under study ablated 34.5% additional vessels attained by bFGF, when both agents were applied in the YSM together on the same disk.
Different from the CAM assay, which is perhaps the most widely employed in vivo model for studying vessel development (angiogenesis) (29, 34) , the YSM assay (31) performed in the current work is a powerful tool for distinguishing between newly-formed microvessels (after application of drug-containing disks on the YSM) and those early vitelline vessels already present on the 2nd embryonic day of chick development. Thus, it is especially noteworthy that the marked reduction in the vascular density on the YSMs and even the eventual permanence of blood islands around the disk limits that was promoted by effective doses of t-resveratrol actually indicate that no new microvessels were present in the area vasculosa. Moreover, the virtual absence of capillary vessels, which would have already been present at hour 36 of the experiment when the disks were implanted, suggests that t-resveratrol has induced regression of earliest vasculature as well as the blood islands during the process of vascular remodeling.
A previous study performed with ovarian cancer metastatic cells, concerning the effects of treatment with resveratrol on the angiogenic factors (35) , revealed inhibition of hypoxia-inducible factor 1α (HIF-1α) and subsequent blockade of VEGF expression and cell migration. The inhibitory mechanisms of resveratrol on endothelial cell growth, migration, and tubulogenesis are not sufficiently clarified, but it has been documented that the inhibition of cell growth by t-resveratrol is associated with suppressive activity of COX enzymes (23, 36) . It was also reported that the COX-1 isoform specifically regulates in the vascular endothelial cells, the process of vessel formation (37) . Moreover, the inhibition of COX synthesis by ASA markedly blocked in vitro angiogenesis mediated by VEGF expression and induction of essential transcription factor (Ets-1) in human umbilical vein endothelial cells (HUVEC) (38) . In the present study, indeed, we have observed that vessel regression (vascular death) on the YSMs is a visible effect from treatment with COX inhibitors such as ASA and indomethacin.
As demonstrated by Sato and collaborators (39) , VEGF stimulates the expression of the essential endothelial transcription factor (Ets-1) as well as matrix metalloproteinases (MMP), flt-1 (the VEGF receptor-1), and DNA synthesis besides proliferation and migration in HUVEC. The intracellular signal transduction of VEGF is mediated by homo-and / or heterodimmers of flt-1 and KDR (the VEGF receptor-2).
On the other hand, it is well known that PKC is a key enzyme in both induction of cell growth and transduction of a signal in the cell membrane, which increases the DAG levels and PKC-α,β1 / 2 activities (DAG-mediated PKC activation pathway) inducing diabetes-related abnormal angiogenesis (40) . Also, there are a number of evidences concerning inhibitory effects on the angiogenesis by several PKC inhibitors such as quercetin and resveratrol (18, 41) . Moreover, phorbol ester (TPA, a PKC activator)-induced tonic contraction of vascular smooth muscle in rat aorta was reversed by flavonoids, indicating a reversible polyphenol tropism by PKC in the blood vessels (for a review, see ref. 19 ).
Other studies, performed in rat pancreatic islets, show that the experimental activation of PKC partially restricts the suppressive action of t-resveratrol in glucose-induced insulin secretion (42, 43) . Conversely, phorbol ester (PMA)-mediated induction of COX-2 mRNA, protein, and prostaglandin synthesis in human mammary and oral epithelial cells was suppressed by resveratrol (44) . In addition, resveratrol was shown to inhibit nitric oxide synthase (iNOS) induction (45) , the expression of tumor necrosis factor (TNF)-α mRNA in endothelial cells, and expressions of TNF-α and interleukin (IL)-1β mRNA in monocytes (46) . All these findings are in agreement with the hypothesis of a direct PKC-mediated inhibitory activity exerted by t-resveratrol in the early processes of vessel formation. When t-resveratrol (43.8 μM/ disk) was co-administered together with a PKC activator (PDBu, 10 μM/ disk) during the 48 h of continuous treatment in the YSMs by means of the delivering drug -MC disk model, its effect increased by 45% the potent vasculogenesis inhibition afforded by PDBu alone (23.5% vs 44% of vessels in the disk limit). As far as this data is concerned, it is plausible to assume that in endothelial cells, the PKC enzyme could be subjected to downregulation induced by PDBu and also to concurrent activity of tresveratrol molecules.
These last results are closely connected with a subject already investigated by Shibley and Pennington (47) . They reported that the non-acute treatment of cultured 5-day-old chick embryo cells with 1 μM phorbol ester (TPA) for 24 h to downregulate (instead of up regulating) PKC activity (and also tyr-K and PKA) significantly increased the amino acid intake and transport [estimated via uptake of N-methylamino-α-isobutyric acid (AIB)], a crucial process for embryonic develop-ment (particularly for embryo growth).
Considering our findings in the treatments with phorbol ester derivative and the evidences of PKC downregulation in non-acute treatments, it may be assumed that this protein kinase should be responsible by a relevant participation in the stimulatory mechanisms on vessel formation. The concept of vasculogenesis inhibition by t-resveratrol, involving the PKC pathway, is consistent with the findings of Xia and collaborators (48) showing that PKC is a principal downstream element of VEGF-initiated signals. Moreover, in accordance with those researchers, two main activators of neovascularization, VEGF and bFGF (used in the current study), mediate mitogenic activity, in part, through PKC activation.
All the treatments by t-resveratrol at doses of 4.38 -43.8 μM/ disk (1 -10 μg / ml) not only were uncoupled from any apparent developmental injury, but also promoted embryonic growth, in spite of the vasculogenesis inhibition, as evidenced by the small but distinct increase in the body total length of the treated embryo groups (Fig. 6 ). These findings may be better understood as consider the data reported by Shibley and Pennington (47) , which are consistent with the current increase in body growth of embryos during a 48-h treatment with t-resveratrol (4.38 -43.8 μM/ disk), suggesting a PKCmediated amino acid uptake. Moreover, the phytoestrogenic properties of t-resveratrol (agonistic activity against estrogen receptors) should be considered (23) . Nevertheless, the apparent inefficacy of t-resveratrol in enhancing the embryonic growth at the dose of 438 μM/disk (100 μg / ml) indicates that this would be a non-specific effect due to the high concentration used (26) . It is particularly noteworthy that t-resveratrol has a polyphenolic chemical structure (with double-bound bridging the two aromatic rings) containing three hydroxyl anion radicals (18) , which are also found in HC molecules. Moreover, the chemical structure of the stilbene under investigation is comparable with that of estradiol and synthetic estrogen diethylstilbestrol (DES, 4,4'-dihydroxy-trans-α,β-diethylstilbene). The similarities are particularly striking for resveratrol and DES, which share the stilbene backbone, and the phenolic-A ring (characteristic of steroidal estrogens) is present in all three compounds (23) . Speculatively, tresveratrol, similarly to glucocorticoids (such as HC, used in the current work as a positive control), could be exerting an angiostatic action via PKC blockade by a partial agonistic effect on the estrogen receptors (32) .
In addition, our findings showed that the treatment with bFGF itself was not capable of significantly modifying the body growth pattern of 4-day chick embryos. However, the co-treatment with bFGF plus tresveratrol (43.8 μM/ disk) abolished the stimulant effect afforded by stilbene alone. Thus we hypothesize, once evidences show that bFGF partially mediates the mitogenic activity through PKC activation (49) , this growth factor could be furnishing an additional target to resveratrol, in this way decreasing its availability.
Increasing attention has been directed to the development of new pharmacological strategies for targeting pathologies involving processes of vessel formation such as neoangiogenesis (12, 50, 51) , for example, in some tumor conditions (tumor neovascularization) (52 -54) . In this regard, natural products potentially combining effectiveness in vasculogenesis inhibition (and improvement in the growth rates) with less toxicity are currently more than a promise. Thus, the finding of the current study, in absence of any obvious dimorphic features and apparent toxicity signs in the early embryos, treated by means of t-resveratrol implants, is quite encouraging.
In conclusion, the findings in the current work demonstrate that the t-resveratrol displays antivasculogenic as well as metabolism stimulant properties evidenced by the increase in the embryo body growth. These effects, which are at least in part due to PKC inhibition, might be instrumental in providing alternative tools to control diseases associated with vascular and nutritional dysfunctions.
